U.S. Food and Drug Administration, Center for Drug Evaluation and Research

FDA Drug Information Soundcast in Clinical Oncology (D.I.S.C.O.)

医学

がん治療、製品承認、安全性の最新情報を探る、このオンコロジーと医薬品開発に焦点を当てた情報豊富なポッドキャストシリーズです。

FDA D.I.S.C.O. Burst Edition: FDA approval of Ryoncil (remestemcel-L-rknd) for steroid-refractory acute graft versus host disease in pediatric patients

3 mins • Jan 17, 2025

Charts

198
Decreased by 31
Apple Podcasts – フランス – 医学
33
NEW
Apple Podcasts – 韓国 – 医学
189
NEW
Apple Podcasts – 韓国 – 健康／フィットネス
59
Decreased by 9
Apple Podcasts – トルコ – 医学
200
NEW
Apple Podcasts – シンガポール – 医学

最近のエピソード

Jan 17, 2025

FDA D.I.S.C.O. Burst Edition: FDA approval of Ryoncil (remestemcel-L-rknd) for steroid-refractory acute graft versus host disease in pediatric patients

3 mins

Dec 30, 2024

FDA D.I.S.C.O. Burst Edition: FDA approval of Bizengri (zenocutuzumab-zbco) for Treatment of adults with advanced unresectable or metastatic pancreatic adenocarcinoma harboring a neuregulin 1 (NRG1) gene fusion with disease progression on or after prior systemic therapy

3 mins

Nov 18, 2024

FDA D.I.S.C.O. Burst Edition: FDA approval of Tecelra (afamitresgene autoleucel) for unresectable or metastatic synovial sarcoma

3 mins

Nov 14, 2024

FDA D.I.S.C.O. Burst Edition: FDA approval of Keytruda (pembrolizumab) for unresectable advanced or metastatic malignant pleural mesothelioma

4 mins

Aug 16, 2024

FDA D.I.S.C.O. Burst Edition: FDA approvals of Augtyro (repotrectinib) for NTRK gene fusion-positive solid tumors and Krazati (adagrasib) for KRAS G12C-mutated colorectal cancer

5 mins

言語

英語

国

アメリカ合衆国

カテゴリー

ウェブサイト

フィード

更新をリクエストする

更新には数分かかる場合があります。

FDA Drug Information Soundcast in Clinical Oncology (D.I.S.C.O.)

FDA D.I.S.C.O. Burst Edition: FDA approval of Ryoncil (remestemcel-L-rknd) for steroid-refractory acute graft versus host disease in pediatric patients

Charts

Apple Podcasts – フランス – 医学

Apple Podcasts – 韓国 – 医学

Apple Podcasts – 韓国 – 健康／フィットネス

Apple Podcasts – トルコ – 医学

Apple Podcasts – シンガポール – 医学

最近のエピソード

FDA D.I.S.C.O. Burst Edition: FDA approval of Ryoncil (remestemcel-L-rknd) for steroid-refractory acute graft versus host disease in pediatric patients

FDA D.I.S.C.O. Burst Edition: FDA approval of Bizengri (zenocutuzumab-zbco) for Treatment of adults with advanced unresectable or metastatic pancreatic adenocarcinoma harboring a neuregulin 1 (NRG1) gene fusion with disease progression on or after prior systemic therapy

FDA D.I.S.C.O. Burst Edition: FDA approval of Tecelra (afamitresgene autoleucel) for unresectable or metastatic synovial sarcoma

FDA D.I.S.C.O. Burst Edition: FDA approval of Keytruda (pembrolizumab) for unresectable advanced or metastatic malignant pleural mesothelioma

FDA D.I.S.C.O. Burst Edition: FDA approvals of Augtyro (repotrectinib) for NTRK gene fusion-positive solid tumors and Krazati (adagrasib) for KRAS G12C-mutated colorectal cancer